By Christopher Gannatti, CFA, Global Head of Research
Key Takeaways
- Despite weak public biotech stock performance, venture capital in private biotech markets remains robust, with 2024 on track to rival 2021’s funding environment.
- Recent breakthroughs in CAR-T and CRISPR therapies are pushing biotech innovation forward, with promising results in autoimmune diseases showing the sector’s long-term growth potential.
- As biotechnology advances through scientific milestones, patient investors may benefit from upcoming therapeutic breakthroughs, even if returns lag in the short term.
In late 2023, we wrote about how we thought that after equity performance challenges for the better part of two years, this year could encapsulate a “comeback” for biotech shares.
If investors judged the veracity of that statement based on the share price performance of publicly listed biotech companies, it has so far proved to be incorrect. However, this may not tell us the full story.
Private Markets Increase in Importance as a Signal
The market for initial public offerings has been fairly quiet since 2021, with the exception of a few bigger names here and there. It appears that companies have gained a certain degree of comfort with staying private for a longer time.
When investors think back to 2021, two characteristics stand out:
- The U.S. Federal Reserve and other central banks had pegged interest rates at exceptionally low levels in order to stimulate economic growth during an uncertain pandemic period.
- Significant fiscal policy stimulus was also working its way through the global economy.
Combined, these ingredients led to a very frothy funding environment for biotechnology venture capitalists, as well as higher price multiples for public market investors. In figure 1, we can see:
- In 2021, there were 106 funding rounds valued at $100 million or more.
- Through the first eight months of 2024, there were 68 funding rounds valued at $100 million or more—which means it’s not impossible that 2024 could be competitive with 2021 when all is said and done. We think this is a powerful signal in that we are not seeing anywhere near the degree of economic stimulus that we were seeing in 2021.
Figure 1: Number of Biotech Venture-Capital Financings of $100 Million or More in the U.S. and Europe
Source: Silicon Valley Bank, as seen in the article: Brian Gormley,
“Venture Mega-Rounds Return to Biotech,” Wall Street Journal,
9/26/24. Past performance is not indicative of future results.
Science Continues Its Forward March
We have written before about chimeric antigen receptor (CAR-T) therapies. The simple, high-level explanation of this is figuring out how to give instructions to a person’s own immune system. There have been cases where certain types of blood cancers have responded well to this approach, but we just read about initial successful applications for certain autoimmune conditions.1
Three individuals from China with severe autoimmune conditions have gone into remission after being treated with bioengineered and CRISPR-modified immune cells. This is the first time people with autoimmune disorders have been treated with engineered immune cells created from donor cells rather than their own. This advance could lead to the mass production of such therapies.
One recipient, Mr. Gong, a 57-year-old man from Shanghai with systemic sclerosis, experienced significant improvements in his condition just days after receiving the therapy. Engineered immune cells, known as chimeric antigen receptor (CAR) T cells, have shown promise in treating blood cancers and autoimmune conditions like lupus and multiple sclerosis. However, using a person’s own immune cells for this therapy is expensive and time-consuming.
Researchers have started creating CAR-T therapies from donated immune cells, which could reduce costs and production times. If successful, one donor’s cells could be used to treat more than 100 people. The trial, led by Xu Huji at Naval Medical University in Shanghai, is the first to report results for autoimmune diseases, with recipients remaining in remission more than six months after treatment.
The process involves extracting T cells from a donor, modifying them with CAR proteins that target B cells and using CRISPR-Cas9 to knock out genes to prevent immune reactions. The first person to receive the treatment was a 42-year-old woman with autoimmune myopathy, followed by Mr. Gong and another man with aggressive sclerosis. The CAR T cells targeted and destroyed pathogenic B cells, leading to significant improvements in symptoms and declines in autoantibody levels.
None of the recipients experienced severe inflammatory reactions or evidence of graft rejection. However, researchers are still investigating long-term safety concerns, such as the emergence of new tumors. The big question now is whether this approach will work in more people and how durable the effects will be.
Conclusion: Science First, Returns Later
We continue to think that biotechnology presently sits on the cusp of a lot of interesting jumps forward in capability. As we see the advances in artificial intelligence and computing power, it’s becoming more and more clear that DNA represents the storage of certain biological information, and if one can process and understand that information, one can use the resulting cells to accomplish valuable tasks.
CAR-T is merely one type of therapy among many that we believe has enormous potential.
1 Source: Smriti Mallapaty, “World-first therapy using donor cells sends autoimmune diseases into remission,” Nature, 10/4/24. Microsoft Co-Pilot assisted with the summary.
This article originally appeared on WisdomTree’s website and is reprinted on VettaFi | ETF Trends with permission from the author. For more information, please visit WisdomTree.com.
Originally published October 18, 2024
For more news, information, and strategy, visit the Modern Alpha Channel.
U.S. investors only: Click here to obtain a WisdomTree ETF prospectus which contains investment objectives, risks, charges, expenses, and other information; read and consider carefully before investing.
There are risks involved with investing, including possible loss of principal. Foreign investing involves currency, political and economic risk. Funds focusing on a single country, sector and/or funds that emphasize investments in smaller companies may experience greater price volatility. Investments in emerging markets, currency, fixed income and alternative investments include additional risks. Please see prospectus for discussion of risks.
Past performance is not indicative of future results. This material contains the opinions of the author, which are subject to change, and should not to be considered or interpreted as a recommendation to participate in any particular trading strategy, or deemed to be an offer or sale of any investment product and it should not be relied on as such. There is no guarantee that any strategies discussed will work under all market conditions. This material represents an assessment of the market environment at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This material should not be relied upon as research or investment advice regarding any security in particular. The user of this information assumes the entire risk of any use made of the information provided herein. Neither WisdomTree nor its affiliates, nor Foreside Fund Services, LLC, or its affiliates provide tax or legal advice. Investors seeking tax or legal advice should consult their tax or legal advisor. Unless expressly stated otherwise the opinions, interpretations or findings expressed herein do not necessarily represent the views of WisdomTree or any of its affiliates.
The MSCI information may only be used for your internal use, may not be reproduced or re-disseminated in any form and may not be used as a basis for or component of any financial instruments or products or indexes. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each entity involved in compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties. With respect to this information, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including loss profits) or any other damages (www.msci.com)
Jonathan Steinberg, Jeremy Schwartz, Rick Harper, Christopher Gannatti, Bradley Krom, Kevin Flanagan, Brendan Loftus, Joseph Tenaglia, Jeff Weniger, Matt Wagner, Alejandro Saltiel, Ryan Krystopowicz, Brian Manby, and Scott Welch are registered representatives of Foreside Fund Services, LLC.
WisdomTree Funds are distributed by Foreside Fund Services, LLC, in the U.S. only.
You cannot invest directly in an index.
